In oral tablet manufacturing for companion animals and young ruminants, particle size distribution of the veterinary-grade API governs blend uniformity and dissolution rate. A direct-compression formulation is viable only when the API has a flowable crystalline habit and a particle size D90 below 180 µm; for low-dose APIs below 25 mg per unit, the D50 is typically controlled between 45 µm and 75 µm to reduce segregation. For cohesive or high-dose APIs exceeding 40% w/w, wet granulation with povidone K30 at 2% w/w to 5% w/w of dry granule mass is used. The granulation endpoint is monitored by impeller torque on a high-shear mixer; a terminal torque range of 4 N·m to 8 N·m at impeller speeds of 150–250 rpm provides sufficient densification without overwetting. Crospovidone at 2% w/w to 6% w/w or sodium starch glycolate at 2% w/w to 5% w/w is added before final blending. Magnesium stearate is limited to 0.5% w/w to 1.0% w/w and blended for 3 min to 5 min at 12 rpm in a V-blender to avoid excessive lubricant coating. Compression is carried out on a rotary tablet press equipped with a force feeder and pre-compression roll; main compression force for 9 mm to 13 mm round boluses typically falls between 8 kN and 25 kN, adjusted to maintain tablet hardness at 40 N to 80 N. Finished units are tested against USP <905> Uniformity of Dosage Units with an acceptance value ≤ 15.0, USP <701> disintegration with a limit of 15 min in water at 37 °C, and USP <1216> friability with weight loss ≤ 1.0%. Residual solvent levels are controlled under VICH GL18; analytical method validation follows VICH GL1. Terminal products include oral boluses for calves and chewable tablets for dogs, with label claims between 10 mg and 1,000 mg of active ingredient per unit depending on target species and veterinary indication.

What Limits Terminal Sterilization of Aqueous Veterinary Injectables?

Aqueous injectable manufacture is constrained by the thermal stability of the API in buffered solution and by the equilibration time required for dissolution before filtration. The formulation sequence starts with API addition to 80% of final Water for Injection volume at 20 °C to 25 °C under nitrogen overlay if the API is oxygen-sensitive. pH is adjusted with 0.1 M hydrochloric acid or sodium hydroxide to a target validated between pH 3.0 and pH 8.5; phosphate or citrate buffers at 10 mM to 50 mM are used when pH drift exceeds 0.2 pH units during accelerated stability screening. Sodium chloride at 0.9% w/v or dextrose at 5% w/v is added for tonicity. Terminal sterilization is acceptable only when the API retains ≥ 95.0% potency after a cycle delivering F0 ≥ 15 min at 121.1 °C according to ISO 17665-1; if forced-degradation studies at 80 °C for 7 days show assay loss above 0.5%, aseptic filtration through a 0.22 µm PVDF membrane is selected instead. For heat-stable formulations, the filled vials are autoclaved at 121.1 °C for 15 min; for heat-labile products, filtration and filling occur under Grade A laminar flow with a Grade B background. Fill volume for multi-dose vials includes an overfill of 0.3 mL to 0.5 mL per 10 mL to meet USP <1> withdrawable volume requirements. Sterility is confirmed by USP <71> and Ph. Eur. 2.6.1; bacterial endotoxin limits are validated per USP <85> and Ph. Eur. 2.6.14. Particulate matter is measured under USP <788> or Ph. Eur. 2.9.19 with limits of ≤ 6,000 particles per container at ≥ 10 µm and ≤ 600 per container at ≥ 25 µm for small-volume parenterals. Terminal dosage forms are 10 mL single-dose vials, 50 mL and 100 mL multi-dose vials for cattle, and 250 mL infusion-compatible presentations for swine.

Water-Soluble Powder Reconstitution and Drinking Line Distribution

Water-soluble powder manufacture for poultry and swine drinking water requires an API particle size D90 below 75 µm to prevent nozzle obstruction in proportioner medicators and to achieve reconstitution in field water at 10 °C to 20 °C. The powder blend typically contains 10% w/w to 50% w/w API, anhydrous lactose or dextrose as water-soluble filler, citric acid at 1% w/w to 3% w/w for pH control, and a suitable dispersant such as poloxamer 188 at 0.1% w/w to 0.5% w/w when the API is hydrophobic. All components are pre-screened through a 60 mesh (250 µm) stainless-steel sieve and blended in a V-blender at 60% to 70% of rated capacity for 20 min to 30 min at 15 rpm to 20 rpm. Blend uniformity is monitored by taking 10 sampling points and requires a coefficient of variation ≤ 5.0%; a CV above 5.0% indicates insufficient screening of lactose or electrostatic retention of API on the blender shell. Packaging is in heat-sealed foil laminate pouches with a moisture vapor transmission rate ≤ 0.5 g/m²/24 h to prevent caking. The reconstituted stock solution is prepared at 10% w/v and delivered through a medicator set between 1% and 5% proportioning, which produces a final drinking-line concentration of 1 mg/mL to 5 mg/mL depending on the approved dose. pH of the reconstituted solution is maintained between 4.0 and 6.5 to avoid precipitation of weakly basic APIs. Dissolution of the powder is tested by adding 5 g to 1 L water at 15 °C with magnetic stirring at 100 rpm; complete dissolution is typically required within 15 min. The terminal product is a water-soluble powder in 100 g, 500 g, and 1 kg foil pouches for broiler, turkey, and pig drinking-line administration.

When medicated premix is incorporated into pelleted swine or poultry feed, the API particle size and carrier affinity determine segregation, dusting, and cross-contamination risk. The veterinary-grade API is dispersed onto a food-grade carrier such as rice hulls, corn cob granules, or calcium carbonate with a carrier particle size between 300 µm and 600 µm. Active loading in the premix is usually 2% w/w to 10% w/w. Mineral oil is added at 1.0% w/w to 2.0% w/w as a binding agent to adhere fine API particles to the carrier surface; oil addition below 1.0% w/w results in visible dusting during transfer, while addition above 2.5% w/w can produce clumping in screw conveyors and bridging in the mixer discharge gate. A horizontal ribbon mixer with a working capacity of 70% to 80% is used at 15 rpm to 20 rpm for 10 min to 15 min. Premix homogeneity is assessed by collecting 10 samples at blender discharge; the target coefficient of variation is ≤ 5.0%, but low-dose APIs intended for final feed concentrations below 10 ppm may require CV ≤ 3.0%. The premix is then diluted in a horizontal paddle mixer at the feed mill at a ratio between 1:20 and 1:100 into the final feed; the exact ratio is calculated from the approved daily intake and the average daily feed consumption of the target species. Carryover is controlled by sequencing non-medicated feed after medicated batches and by flushing the production line with 50 kg to 100 kg of ground corn or carrier. Cross-contamination limits for non-target feed are controlled under EU Regulation 2019/4/EC Annex II; worst-case carryover is typically targeted below 1% of the active concentration in the previous medicated batch. Terminal products are 5% w/w and 10% w/w medicated premixes packed in 25 kg paper bags with polyethylene liners, intended for swine grower-finisher rations and poultry broiler feeds.

When Low-Dose APIs Require Content Uniformity in Gelatin Capsules

Low-dose capsule filling for companion animals becomes technically demanding when the active ingredient is below 1 mg per capsule because direct blending without pre-dispersion can produce acceptance value failures under USP <905>. The API is first micronized to a D90 ≤ 10 µm and then pre-mixed by geometric dilution in 1:10 steps with microcrystalline cellulose PH-102 or lactose monohydrate 200 mesh. The final fill formulation includes croscarmellose sodium at 2% w/w to 5% w/w as disintegrant, colloidal silicon dioxide at 0.5% w/w to 1.0% w/w as glidant, and magnesium stearate at 0.5% w/w added as the final blending component. Final blending is performed in a twin-shell blender at 25 rpm for 15 min; blending beyond 30 min is avoided because magnesium stearate over-coating reduces capsule dissolution at USP <711> sampling times. Capsule filling is carried out on a tamping-pin machine at fill weights between 150 mg and 400 mg, using gelatin or HPMC capsules from size 4 through size 1. When gelatin capsules are used, the filling suite is maintained at 20 °C to 25 °C and relative humidity below 40% to prevent shell deformation and cross-linking. In-process checks include weight variation every 15 min on 10 capsules and content uniformity by HPLC on 10 units at start, middle, and end of the batch. Disintegration is tested per USP <701> with a limit of 15 min in water at 37 °C. Finished products are oral capsules for dogs and cats, often at strengths of 1 mg to 50 mg per capsule, packed in HDPE bottles with desiccant to maintain water activity below 0.6 after 24 h at 25 °C and 60% RH.

During fluid-bed granulation of oral suspension powders, residual moisture and granule size distribution determine downstream sachet filling and reconstitution behavior. A binder solution of povidone K30 at 5% w/w in purified water is sprayed at 2 g/min/kg to 3 g/min/kg of dry powder bed in a top-spray fluid-bed granulator. Inlet air temperature is held between 55 °C and 70 °C, product temperature between 30 °C and 40 °C, and the drying endpoint is controlled by loss on drying between 1.0% w/w and 2.0% w/w measured by a halogen moisture analyzer at 105 °C. For high-shear granulation, an impeller torque of 3 N·m to 6 N·m at 200 rpm and chopper speed 1,500 rpm marks the transition from wet mass to agglomerates. The dried granules are milled through a conical mill fitted with an 813 µm screen at 1,500 rpm; the target granule fraction between 150 µm and 850 µm should be ≥ 80% w/w. Sachet filling is performed on a form-fill-seal line with nitrogen flushing when the API is oxidation-sensitive; residual oxygen in the headspace is maintained below 2.0%. For reconstituted oral suspensions, xanthan gum at 0.2% w/v to 0.5% w/v is used to achieve a sedimentation volume ratio F ≥ 0.9 after 4 h at 25 °C. Viscosity of the reconstituted suspension is controlled below 500 mPa·s at 25 °C using a rotational viscometer at 60 rpm. The terminal product is a granule for oral suspension packed in 10 g to 100 g sachets for piglets and calves.